Table 3 A summary of the pathology detection patterns of aSyn non-modified and PTM antibodies on LBD substantia nigra.

From: Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases

Antibody

Neuronal

Glial

Extrasomal

LBs

Diffuse cytoplasmic with an aggregate

Punctate cytoplasmic

LNs & neuropil dots

Astroglial

Coiled body-like oligodendroglial

LASH-EGTNter 1–20

++

++

++

+

+

LASH-BL 34–45

+++

+

+++

+++

+++

+

+

LASH-BL 80–96

++

+

++

++

++

+

+

BD SYN-1 91–99

++

+

++

++

++

+

+

2F10-E12 110–115

+++

++

+++

++

+

AB 134–138

++

++

++

+

LASH-BL pY39

+

–/+

+

+

+

+

LASH pS87

+

+

–/+

+

+

AB pY125

+

–/+

AB EP1536Y pS129

+++

++

+++

+

+

AB pY133

+

+

+

+

AB pY136

++

++

+

LASH-EGT nY39

+

+

++

+

++

++

6A3-E9 aSyn-120

+

++

  1. absent, + mild, ++ moderate, +++ frequent, aSyn alpha-synuclein, LB Lewy body, LBD Lewy body disease, LN Lewy neurite, PTM post-translational modification.